Alzheimer’s plaques decline after CAR-T immune cell treatment in preclinical study
Researchers engineered CD4+ chimeric antigen receptor T cells targeting fibrillar amyloid beta and tested them in a mouse Alzheimer model. The preclinical study showed reduced